JP2013503168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013503168A5 JP2013503168A5 JP2012526918A JP2012526918A JP2013503168A5 JP 2013503168 A5 JP2013503168 A5 JP 2013503168A5 JP 2012526918 A JP2012526918 A JP 2012526918A JP 2012526918 A JP2012526918 A JP 2012526918A JP 2013503168 A5 JP2013503168 A5 JP 2013503168A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- tocotrienol quinone
- item
- subject
- cerebral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 67
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 42
- LNOVHERIIMJMDG-KTWAZNHYSA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O LNOVHERIIMJMDG-KTWAZNHYSA-N 0.000 claims description 20
- 230000002490 cerebral effect Effects 0.000 claims description 20
- 230000000302 ischemic effect Effects 0.000 claims description 15
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims description 13
- 229930003802 tocotrienol Natural products 0.000 claims description 13
- 239000011731 tocotrienol Substances 0.000 claims description 13
- 235000019148 tocotrienols Nutrition 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 7
- 208000028389 Nerve injury Diseases 0.000 claims description 6
- 208000012268 mitochondrial disease Diseases 0.000 claims description 6
- 230000008764 nerve damage Effects 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 210000005166 vasculature Anatomy 0.000 claims description 5
- FGYKUFVNYVMTAM-UHFFFAOYSA-N (R)-2,5,8-trimethyl-2-(4,8,12-trimethyl-trideca-3t,7t,11-trienyl)-chroman-6-ol Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-UHFFFAOYSA-N 0.000 claims description 4
- SFVAYPRWECRHTF-QRCIITMISA-N 2-[(6e,10e)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trienyl]-6-methylcyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)(O)CCC1=CC(=O)C=C(C)C1=O SFVAYPRWECRHTF-QRCIITMISA-N 0.000 claims description 4
- RZFHLOLGZPDCHJ-DLQZEEBKSA-N alpha-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(/CC/C=C(\CC/C=C(\C)/C)/C)\C)(C)CCc2c1C RZFHLOLGZPDCHJ-DLQZEEBKSA-N 0.000 claims description 4
- FGYKUFVNYVMTAM-YMCDKREISA-N beta-Tocotrienol Natural products Oc1c(C)c2c(c(C)c1)O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CC2 FGYKUFVNYVMTAM-YMCDKREISA-N 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- FGYKUFVNYVMTAM-MUUNZHRXSA-N epsilon-Tocopherol Natural products OC1=CC(C)=C2O[C@@](CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-MUUNZHRXSA-N 0.000 claims description 4
- 235000019151 β-tocotrienol Nutrition 0.000 claims description 4
- 239000011723 β-tocotrienol Substances 0.000 claims description 4
- FGYKUFVNYVMTAM-WAZJVIJMSA-N β-tocotrienol Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C FGYKUFVNYVMTAM-WAZJVIJMSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 206010030113 Oedema Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 208000037906 ischaemic injury Diseases 0.000 claims description 2
- 230000016273 neuron death Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- -1 .gamma.-tocotrienol quinones Chemical class 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 229940064063 alpha tocotrienol Drugs 0.000 claims 1
- RZFHLOLGZPDCHJ-XZXLULOTSA-N α-Tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1C RZFHLOLGZPDCHJ-XZXLULOTSA-N 0.000 claims 1
- 235000019145 α-tocotrienol Nutrition 0.000 claims 1
- 239000011730 α-tocotrienol Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 29
- OTXNTMVVOOBZCV-UHFFFAOYSA-N 2R-gamma-tocotrienol Natural products OC1=C(C)C(C)=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-UHFFFAOYSA-N 0.000 description 3
- OTXNTMVVOOBZCV-YMCDKREISA-N gamma-Tocotrienol Natural products Oc1c(C)c(C)c2O[C@@](CC/C=C(\CC/C=C(\CC/C=C(\C)/C)/C)/C)(C)CCc2c1 OTXNTMVVOOBZCV-YMCDKREISA-N 0.000 description 3
- 235000019150 γ-tocotrienol Nutrition 0.000 description 3
- 239000011722 γ-tocotrienol Substances 0.000 description 3
- OTXNTMVVOOBZCV-WAZJVIJMSA-N γ-tocotrienol Chemical compound OC1=C(C)C(C)=C2O[C@@](CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 OTXNTMVVOOBZCV-WAZJVIJMSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27526909P | 2009-08-26 | 2009-08-26 | |
| US61/275,269 | 2009-08-26 | ||
| PCT/US2010/046503 WO2011025785A1 (en) | 2009-08-26 | 2010-08-24 | Methods for the prevention and treatment of cerebral ischemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027506A Division JP2015091899A (ja) | 2009-08-26 | 2015-02-16 | 脳虚血を予防または処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013503168A JP2013503168A (ja) | 2013-01-31 |
| JP2013503168A5 true JP2013503168A5 (enExample) | 2013-10-10 |
| JP5785546B2 JP5785546B2 (ja) | 2015-09-30 |
Family
ID=42983642
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012526918A Expired - Fee Related JP5785546B2 (ja) | 2009-08-26 | 2010-08-24 | 脳虚血を予防または処置する方法 |
| JP2015027506A Pending JP2015091899A (ja) | 2009-08-26 | 2015-02-16 | 脳虚血を予防または処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015027506A Pending JP2015091899A (ja) | 2009-08-26 | 2015-02-16 | 脳虚血を予防または処置する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20110207828A1 (enExample) |
| EP (1) | EP2470168B1 (enExample) |
| JP (2) | JP5785546B2 (enExample) |
| CN (1) | CN102647981B (enExample) |
| AU (1) | AU2010286704B2 (enExample) |
| BR (1) | BR112012004167A2 (enExample) |
| CA (1) | CA2772294C (enExample) |
| DK (1) | DK2470168T3 (enExample) |
| EA (1) | EA028677B1 (enExample) |
| ES (1) | ES2663709T3 (enExample) |
| HU (1) | HUE037592T2 (enExample) |
| MX (1) | MX337990B (enExample) |
| NO (1) | NO2470168T3 (enExample) |
| PL (1) | PL2470168T3 (enExample) |
| PT (1) | PT2470168T (enExample) |
| SI (1) | SI2470168T1 (enExample) |
| WO (1) | WO2011025785A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005032544A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Treatment of mitochondrial diseases |
| ES2714900T3 (es) | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| SI3456707T1 (sl) | 2007-11-06 | 2020-10-30 | Ptc Therapeutics, Inc. | Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni |
| WO2009089224A1 (en) * | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
| JP5710277B2 (ja) | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| JP2012502064A (ja) | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
| WO2010045220A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| MY157119A (en) | 2008-10-28 | 2016-05-13 | Edison Pharmaceuticals Inc | Process for the production of alpha-tocotrienol and derivatives |
| HUE037574T2 (hu) | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| CA2797644A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| CA2797581A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
| SI2680873T1 (sl) | 2011-03-03 | 2017-12-29 | Cidara Therapeutics, Inc. | Protiglivna sredstva in njihova uporaba |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| JP2014520894A (ja) | 2011-07-19 | 2014-08-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | 非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法 |
| GB201117808D0 (en) * | 2011-10-14 | 2011-11-30 | Siemens Medical Solutions | SUV correction following dose infiltration |
| PL3677252T3 (pl) * | 2012-03-19 | 2024-01-08 | Cidara Therapeutics, Inc. | Schematy dawkowania dla związków z klasy echinokandyn |
| CA2883882A1 (en) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| CN112451518B (zh) * | 2012-11-13 | 2025-02-21 | 因维克特斯生物技术有限公司 | 生育三烯酚的经粘膜递送 |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| CA2906145A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| RU2578451C1 (ru) * | 2014-12-09 | 2016-03-27 | Государственное Бюджетное Образовательное Учреждение Высшего Профессионального Образования "Амурская Государственная Медицинская Академия" Министерства Здравоохранения Российской Федерации | Способ повышения устойчивости головного мозга к ишемии во время реконструктивных операций на брахиоцефальных артериях |
| WO2016100579A1 (en) | 2014-12-16 | 2016-06-23 | Edison Pharmaceuticals, Inc., | Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| ES2955711T3 (es) | 2016-03-16 | 2023-12-05 | Cidara Therapeutics Inc | Regímenes de dosificación para el tratamiento de infecciones fúngicas |
| US10707531B1 (en) | 2016-09-27 | 2020-07-07 | New Dominion Enterprises Inc. | All-inorganic solvents for electrolytes |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| CN111050798A (zh) | 2017-07-12 | 2020-04-21 | 奇达拉治疗公司 | 用于治疗真菌感染的组合物和方法 |
| MX2021000157A (es) * | 2018-07-03 | 2021-12-10 | Venturis Therapeutics Inc | Composiciones y métodos para tratar el derrame cerebral. |
| KR102337954B1 (ko) * | 2018-08-16 | 2021-12-10 | 차의과학대학교 산학협력단 | 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법 |
| FI3866772T3 (fi) | 2018-10-17 | 2024-01-11 | Ptc Therapeutics Inc | 2,3,5-trimetyyli-6-nonyylisykloheksa-2,5-dieeni-1,4-dioni alfa-synukleinopatioiden, tauopatioiden ja muiden häiriöiden estämiseen ja hoitoon |
| CA3156499A1 (en) | 2019-10-04 | 2021-04-08 | Stealth Biotherapeutics Inc. | CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS |
| JP2022552002A (ja) * | 2019-10-17 | 2022-12-14 | ザ・ペン・ステイト・リサーチ・ファウンデイション | 出血性脳卒中の治療のための機能的ニューロンの再生 |
| EP4126836A1 (en) | 2020-04-03 | 2023-02-08 | Stealth BioTherapeutics Inc. | Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia |
| CN116762096A (zh) * | 2020-12-22 | 2023-09-15 | 皇家飞利浦有限公司 | 定位血管收缩 |
| CN113066113B (zh) * | 2021-04-27 | 2022-01-11 | 河北医科大学第二医院 | 自发性高血压大鼠脑模板和地图集的构建方法及设备 |
| CN118175991A (zh) | 2021-07-08 | 2024-06-11 | Ptc医疗公司 | 包含2,3,5-三甲基-6-壬基环己-2,5-二烯-1,4-二酮的药物组合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5938203B2 (ja) * | 1976-04-26 | 1984-09-14 | エーザイ株式会社 | 補酵素ｑを主成分とする脳循環障害治療剤 |
| US5872108A (en) * | 1995-03-06 | 1999-02-16 | Interneuron Pharmaceuticals, Inc. | Reduction of infarct volume using citicoline |
| US6232060B1 (en) * | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) * | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| FR2753098B1 (fr) * | 1996-09-06 | 1998-11-27 | Sod Conseils Rech Applic | Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene |
| EP1037628A4 (en) | 1997-11-17 | 2002-08-21 | Lipogenics Inc | METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE |
| US6048891A (en) * | 1998-12-17 | 2000-04-11 | Loma Linda University Medical Center | Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6426362B1 (en) * | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) * | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| US6346544B2 (en) * | 2000-03-02 | 2002-02-12 | Oklahoma Medical Research Foundation | Desmethyl tocopherols for protecting cardiovascular tissue |
| DE10034233A1 (de) * | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
| US20020132845A1 (en) * | 2000-12-15 | 2002-09-19 | Miller Guy Michael | Compositions and methods for the prevention and treatment of tissue ischemia |
| US7034054B2 (en) * | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6608196B2 (en) * | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| MXPA04001555A (es) * | 2001-08-21 | 2004-10-27 | Galileo Pharmaceuticals Inc | Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios. |
| WO2003043570A2 (en) * | 2001-11-15 | 2003-05-30 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US20040152764A1 (en) * | 2001-12-14 | 2004-08-05 | Miller Guy M. | Compositions and methods for the prevention and treatment of cerebral ischemia |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| US7078541B2 (en) * | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| EP1558922B1 (en) * | 2002-10-30 | 2013-02-27 | Ampere Life Sciences, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| WO2005032544A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Treatment of mitochondrial diseases |
| US7393662B2 (en) * | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| ES2714900T3 (es) * | 2005-06-01 | 2019-05-30 | Bioelectron Tech Corp | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| WO2007035496A1 (en) * | 2005-09-15 | 2007-03-29 | Edison Pharmaceuticals, Inc. | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2007100652A2 (en) * | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EP2101808A4 (en) * | 2007-01-10 | 2011-11-30 | Edison Pharmaceuticals Inc | TREATMENT OF BREATHLY TROUBLES USING COMPOUNDS OF ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY |
| SI3456707T1 (sl) * | 2007-11-06 | 2020-10-30 | Ptc Therapeutics, Inc. | Derivati 4-(P-kuinonil)-2-hidroksibutanamida za zdravljenje mitohondrijske bolezni |
| EP2242506A4 (en) * | 2008-01-07 | 2011-12-28 | Janssen Biotech Inc | METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS |
| WO2009089224A1 (en) * | 2008-01-08 | 2009-07-16 | Edison Pharmaceuticals, Inc. | (HET) ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES |
| WO2009111543A2 (en) * | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments with redox-active therapeutics |
| JP5710277B2 (ja) * | 2008-03-05 | 2015-04-30 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体 |
| WO2009140382A2 (en) * | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| EP2303309A2 (en) * | 2008-05-22 | 2011-04-06 | Edison Pharmaceuticals, Inc. | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| JP5798481B2 (ja) * | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| WO2010005989A1 (en) * | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) * | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| JP2012502064A (ja) * | 2008-09-10 | 2012-01-26 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化還元活性治療剤を用いての広汎性発達障害の処置 |
| WO2010045220A1 (en) * | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| MY157119A (en) * | 2008-10-28 | 2016-05-13 | Edison Pharmaceuticals Inc | Process for the production of alpha-tocotrienol and derivatives |
| HUE037574T2 (hu) * | 2009-04-28 | 2018-09-28 | Bioelectron Tech Corp | Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal |
| US20100273892A1 (en) * | 2009-04-28 | 2010-10-28 | Miller Guy M | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases |
| JP2012525398A (ja) * | 2009-04-28 | 2012-10-22 | アンペア ライフ サイエンシーズ，インコーポレイテッド | 眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用 |
| EP2609921A1 (en) * | 2009-06-25 | 2013-07-03 | Ampere Life Sciences, Inc. | Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts |
| CA2797644A1 (en) * | 2009-12-31 | 2011-07-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| WO2011126998A1 (en) * | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| CA2797581A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
| WO2012009271A1 (en) * | 2010-07-14 | 2012-01-19 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| US20120295985A1 (en) * | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
-
2010
- 2010-08-24 CA CA2772294A patent/CA2772294C/en active Active
- 2010-08-24 MX MX2012002374A patent/MX337990B/es active IP Right Grant
- 2010-08-24 WO PCT/US2010/046503 patent/WO2011025785A1/en not_active Ceased
- 2010-08-24 JP JP2012526918A patent/JP5785546B2/ja not_active Expired - Fee Related
- 2010-08-24 AU AU2010286704A patent/AU2010286704B2/en not_active Ceased
- 2010-08-24 ES ES10747777.0T patent/ES2663709T3/es active Active
- 2010-08-24 PT PT107477770T patent/PT2470168T/pt unknown
- 2010-08-24 CN CN201080048363.2A patent/CN102647981B/zh not_active Expired - Fee Related
- 2010-08-24 SI SI201031644T patent/SI2470168T1/en unknown
- 2010-08-24 DK DK10747777.0T patent/DK2470168T3/en active
- 2010-08-24 HU HUE10747777A patent/HUE037592T2/hu unknown
- 2010-08-24 US US12/862,705 patent/US20110207828A1/en not_active Abandoned
- 2010-08-24 PL PL10747777T patent/PL2470168T3/pl unknown
- 2010-08-24 EP EP10747777.0A patent/EP2470168B1/en active Active
- 2010-08-24 EA EA201200355A patent/EA028677B1/ru not_active IP Right Cessation
- 2010-08-24 NO NO10747777A patent/NO2470168T3/no unknown
- 2010-08-24 BR BR112012004167A patent/BR112012004167A2/pt not_active Application Discontinuation
-
2015
- 2015-02-16 JP JP2015027506A patent/JP2015091899A/ja active Pending
-
2016
- 2016-02-10 US US15/040,961 patent/US20170007553A1/en not_active Abandoned
-
2018
- 2018-08-09 US US16/100,062 patent/US20180344667A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013503168A5 (enExample) | ||
| ES2660831T3 (es) | Derivados de imidazol condensados útiles como inhibidores de IDO | |
| US6114317A (en) | Method of locking 1α-OH of vitamin D compounds in axial orientation | |
| JP2014528914A5 (enExample) | ||
| SI2470168T1 (en) | Procedures for the prevention and treatment of brain ischemia | |
| JP7241856B2 (ja) | ビス第四級アンモニウム化合物及びその製造方法と使用 | |
| JP2019515908A5 (enExample) | ||
| JP2001521492A (ja) | １−フェニル−４−ベンジルピペラジン：ドーパミン受容体サブタイプ特異性リガンド（ｄ４） | |
| WO2009020565A1 (en) | Use of phosphates to treat neuroblastomas and medullogastomas | |
| JPWO2020109806A5 (enExample) | ||
| RU2014115796A (ru) | Модуляторы ror-гамма | |
| CA2765086C (en) | Iminosugars and methods of treating bunyaviral and togaviral diseases | |
| JP2015519358A (ja) | スルフォラファンの単離及び精製 | |
| ES2579628T3 (es) | Iminoazúcares y métodos de tratamiento de enfermedades virales | |
| US20150265549A1 (en) | Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone | |
| CA2772813A1 (en) | Iminosugars and methods of treating filoviral diseases | |
| JP2008531602A (ja) | 抗癌特性を有する化合物 | |
| CN118684661A (zh) | 杂芳基类化合物及其药物组合物、制备方法和用途 | |
| US3781273A (en) | N(6)-benzyl-adenosine compounds and therapeutic compositions | |
| JP2014530204A5 (enExample) | ||
| WO2011153353A1 (en) | Tocopherol derivatives and methods of use | |
| US20150335624A1 (en) | Compositions and methods for using huperzine and analogs thereof | |
| EP4362923A1 (en) | Pharmacological agents for preventing and treating cataracts and presbyopia eye diseases | |
| JPH02160720A (ja) | 医薬組成物 | |
| WO1997002822A1 (en) | Drug for ameliorating brain diseases |